P2.04-26 Interim Results from a Phase I/II Trial of Nivolumab in Combination with CIMAvax-EGF as Second-Line Therapy in Advanced NSCLC

作者： G. Dy , A. Dozier , M. Reid , K. Lee , A. Miller

DOI: 10.1016/J.JTHO.2018.08.1250

关键词: Oncology 、 Nivolumab 、 Internal medicine 、 Phase i ii 、 CimaVax-EGF 、 Medicine 、 Second-line therapy 、 Interim